Studies new ways to detect harmful lung bacteria in people with cystic fibrosis
Looks for better ways to find harmful lung bacteria in people with cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
Key facts
- Where
- Columbus, Dallas, La Jolla, Milwaukee, Minneapolis, Omaha, Philadelphia, Pittsburgh, and St Louis, United StatesSee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cystic fibrosis who are 16 or older and can cough up sputum. It tests new ways to find harmful lung bacteria.
- Age
- 16 years or older
- Sex
- All sexes
- Disease stage
- Cystic fibrosis with a documented diagnosis. Percent predicted FEV1 must be 30% or higher.
Main reasons for not taking part
- History of solid organ transplant
- Active cancer, or cancer treatment, in the 12 months before the study visit
- Pregnant
- Cannot cough up sputum
Read by machine on 9 November 2026.
Where in United States
- Nationwide Children's HospitalColumbus, United StatesNot yet recruiting
- University of Texas, SouthwesternDallas, United StatesTaking people
- University of California San DiegoLa Jolla, United StatesNot yet recruiting
- Froedtert & Medical College of WisconsinMilwaukee, United StatesTaking people
- The Minnesota Cystic Fibrosis CenterMinneapolis, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesNot yet recruiting
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chris Goss
- Trial code
- NCT07312734
- Record updated
- 2 July 2026
- Original description
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.Read full original descriptionShow less
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF (SEND-CF)
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Inclusion: ≥ 16 years of age on day of study visit; Documentation of CF Diagnosis; Able to expectorate sputum; Percent predicted FEV1 ≥ 30%.
Exclusion: History of active malignancy (or treatment for malignancy) in 12 months prior to the study visit; History of solid organ transplantation; Pregnant.